We are live on ! Find out more
RPRX icon

Repros Therapeutics
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

58 hedge funds and large institutions have $104M invested in Repros Therapeutics in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more call options, than puts

Call options by funds: $12.7M | Put options by funds: $3.38M

3.87% less ownership

Funds ownership: 61.25% → 57.38% (-3.9%)

9% less funds holding

Funds holding: 64 → 58 (-6)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

44% less capital inflows, than outflows

Capital inflows: $8.55M | Capital outflows: $15.3M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
58
Holders Change
-6
Holders Change %
-9.38%
% of All Funds
1.62%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
13
Increased
13
Reduced
17
Closed
19
Calls
$12.7​M
Puts
$3.38​M
Net Calls
+$9.31​M
Net Calls Change
+$9.09​M

RPRX Hedge Fund Activity: Q3 2015 in Review

58 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q3 2015, worth a combined $104M — down 2.5% from $106M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RPRX and 13 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 13 added.

The largest buyer was Morgan Stanley, adding an estimated $2.76M. The largest seller was Millennium Management, cutting an estimated $3.01M.

  • 58 institutional investors held Repros Therapeutics (RPRX) as of Q3 2015, down from 64 in Q2 2015.
  • Funds reported $104M of Repros Therapeutics stock for Q3 2015, down 2.5% quarter-over-quarter.
  • 13 funds opened new Repros Therapeutics positions in Q3 2015 and 19 closed out, a net change of -6 holders.
  • The largest Repros Therapeutics buyer in Q3 2015 was Morgan Stanley, an estimated $2.76M added.
  • The largest Repros Therapeutics seller in Q3 2015 was Millennium Management, an estimated $3.01M sold.

Based on aggregated 13F filings for Q3 2015.